Logo-jrip
ePublished: 26 Aug 2016
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. 2017;6(1): 65-69.
doi: 10.15171/jrip.2017.12
PMID: 28487875
PMCID: PMC5414522
Scopus ID: 85040674323
  Abstract View: 3274
  PDF Download: 1958

Original Article

Impact of sertraline on serum concentration of CRP in hemodialysis patients with depression

Narges Sadat Zahed, Marjan Sharifi*, Mahdi Karimi, Hajar Nikbakht

1 Loghman Hakim Clinical Research Development Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
*Corresponding Author: *Corresponding author: Marjan Sharifi,, Email: lcrdc.sbum@gmail.com

Abstract

Introduction: Depression is the most prevalent psychological problem among hemodialysis (HD) patients. Inflammatory factors have been reported to play an important role in the pathogenesis of depression. The association between depression and inflammatory factors was established in chronic kidney disease (CKD) patients. Sertraline, a selective serotonin reuptake inhibitor (SSRI) antidepressant, decreases serum levels of inflammatory factors in patients with depression.

Objectives: This study was designed to assess the effect of sertraline on serum concentration of C-reactive protein (CRP), hemoglobin and albumin of depressed hemodialysis (HD) patients.

Patients and Methods: During a clinical trail, 35 depressed HD patients, and CRP >5 were allocated to receive sertraline for 12 weeks. Patients’ depression was assessed using Beck depression inventory second edition (BDI-II) biochemical parameters (hemoglobin, serum albumin, etc) and CRP levels were measured at baseline and at weeks 4, 8 and 12 of the study. BDI-II score was evaluated before and after 12 weeks treatment with sertraline.

Results: Sertraline significantly improved depression symptoms in HD patients. At the end of the study, BDI-II scores significantly changed from baseline (P=0.001) and serum levels of CRP significantly decreased at week 12 of initiation of the study (P=0.001). However, the concentration of hemoglobin and serum albumin concentration and weight was not changed significantly (P=0.995 and P=0.328, respectively).

Conclusion: Sertraline significantly decreases CRP levels and can be a promising strategy to reduce the systemic inflammation and to treat depression in HD patients.


Implication for health policy/practice/research/medical education:

Depression is the most prevalent psychological problem among hemodialysis (HD) patients. Inflammatory factors have been reported to play an important role in the pathogenesis of depression. Patients’ depression was assessed using Beck depression inventory second edition (BDI-II) biochemical parameters and C-reactive protein (CRP) levels were measured at baseline and at weeks 4, 8 and 12 of the study. This study was designed to assess the effect of sertraline on serum concentrations of CRP, hemoglobin and albumin of depressed HD patients. Sertraline significantly decreases CRP levels and can be a promising strategy to reduce the systemic inflammation and to treat depression in HD patients.

Please cite this paper as: Zahed NS, Sharifi M, Karimi M, Nikbakht H. Impact of sertraline on serum concentration of CRP in hemodialysis patients with depression. J Renal Inj Prev. 2017;6(1):65-69. DOI: 10.15171/jrip.2017.12.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 3275

Your browser does not support the canvas element.


PDF Download: 1958

Your browser does not support the canvas element.